Genetic analysis of the E2 transactivation domain dimerization interface from bovine papillomavirus type 1  by Gagnon, David et al.
Virology 439 (2013) 132–139Contents lists available at SciVerse ScienceDirectVirology0042-68
http://d
n Corr
Clinique
H2W 1R
E-m
1 Bojournal homepage: www.elsevier.com/locate/yviroGenetic analysis of the E2 transactivation domain dimerization interface
from bovine papillomavirus type 1David Gagnon a,1, He´lene Se´ne´chal a,1, Claudia M. D’Abramo a, Jennifer Alvarez a,
Alison A. McBride b, Jacques Archambault a,n
a Molecular Virology Laboratory, Institut de Recherches Cliniques de Montre´al (IRCM) and Department of Biochemistry, Universite´ de Montre´al, Montreal, QC, Canada
b Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USAa r t i c l e i n f o
Article history:
Received 1 December 2012
Returned to author for revisions
11 February 2013
Accepted 13 February 2013
Available online 11 March 2013
Keywords:
BPV1
E2
Transactivation
DNA replication
Transactivation domain
Dimer
Dimerization
Redox
High-throughput assay
Protein interface22/$ - see front matter & 2013 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2013.02.012
espondence to: Laboratory of Molecular Viro
s de Montre´al, 110 Pine Avenue West, Mont
7.Fax: þ1 514 987 5741.
ail address: jacques.archambault@ircm.qc.ca
th authors contributed equally to this work.a b s t r a c t
The bovine papillomavirus type 1 (BPV1) E2 protein binds as a dimer to the viral genome to promote its
transcription, replication and maintenance in keratinocytes. Although BPV1 E2 dimerizes primarily
through its DNA-binding domain, it was shown previously that its transactivation domain (TAD) can
also dimerize in vitro through formation of a disulﬁde bond between cysteine 57 (C57) of adjacent
monomers and of an ion pair between arginine 172 (R172) and aspartic acid 175 (D175). The function
of this TAD dimerization interface in vivo remains unknown. Here, we report the effects of substituting
C57, R172 and D175 by alanine on the transactivation activity of BPV E2 as well as on its ability to
support viral DNA replication using a novel luciferase-based assay. Results for this mutational analysis
suggest that the TAD dimerization interface is not essential for either process but may contribute to the
DNA replication activity of BPV1 E2.
& 2013 Elsevier Inc. All rights reserved.Introduction
Papillomaviruses are double-stranded DNA viruses that induce
benign and malignant hyperproliferative lesions of the differentiat-
ing epithelium (Hebner and Laimins, 2006; Howley and Lowy, 2001;
zur Hausen and de Villier, 1994). The life cycle of papillomaviruses is
coupled to the cellular differentiation program that keratinocytes
undergo within the epithelium (Doorbar, 2005; Howley and Lowy,
2001; Longworth and Laimins, 2004). These viruses infect the basal
cell layer where they maintain their double-stranded DNA genome
as a circular episome in the nucleus of infected cells. Maintenance of
the episome in these cells requires the activities of the viral E2
protein, a regulatory factor that binds to speciﬁc sites in the long-
control-region (LCR) of the viral genome to promote its replication,
regulate its transcription and ensure its segregation to daughter cells
in mitosis (Blachon and Demeret, 2003). As a transcription factor, E2
can either activate or repress transcription, depending on thell rights reserved.
logy, Institut de Recherches
real (Quebec), Canada,
(J. Archambault).promoter context (Bernard, 2002). E2 is comprised of two functional
domains, an N-terminal transactivation domain (TAD) and a
C-terminal DNA-binding domain (DBD) separated by a hinge region.
The TAD is a protein interaction module that binds to the viral E1
helicase and to host proteins such as TopBP1 (Donaldson et al.,
2012), and possibly also to RPA (Li and Botchan, 1993) and
topoisomerase I (Clower et al., 2006) which were reported to
interact with full-length E2, to promote replication of the viral
genome. The E2 TAD also associates with cellular transcription
factors, including the bromodomain containing protein 4 (Brd4), to
regulate viral gene transcription (Abbate et al., 2004, 2006; Benson
and Howley, 1995; Sakai et al., 1996; Wu and Chiang, 2007). Brd4
was ﬁrst identiﬁed as the cellular chromatin component that is
bound by the bovine papillomavirus type 1 (BPV1) E2 to tether the
viral episome to host chromosomes in order to prevent its loss
during mitosis (You et al., 2004, 2005). Subsequent studies revealed
that Brd4 is also needed for E2 to activate or repress transcription
(Baxter et al., 2005; Gagnon et al., 2009; McPhillips et al., 2006;
Schweiger et al., 2006; Senechal et al., 2007;Wu et al., 2006). Several
crystal structures of the E2 TAD, either alone (free form) or in
complex with the C-terminal helicase domain of E1, or with a Brd4
peptide, have been reported (Abbate et al., 2004, 2006; Antson et al.,
2000; Harris and Botchan, 1999; Sanders et al., 2007; Wang et al.,
D. Gagnon et al. / Virology 439 (2013) 132–139 1332004). These structures revealed that the E2 TAD has an L-shape
comprised of three anti-parallel a-helices followed by a b-sheet
region (Fig. 1) (Sanders et al., 2007). They also revealed that E1 and
Brd4 bind on opposite faces of the TAD.
E2 binds to DNA as a dimer and is also dimeric in solution.
Its main dimerization interface is located within the C-terminal DBD
(Hegde, 2002). However, the arrangement of the N-terminal TAD
within the lattices of some of the crystal structures mentioned
above suggested that this domain can also homodimerize, but
through different surfaces depending on the papillomavirus type.
For E2 from human papillomavirus type 16 (HPV16), dimerization of
the TAD was found to involve two of the three a-helices that form
part of the Brd4-binding surface (Antson et al., 2000). This TAD–TAD
interface was shown to occur between different E2 dimers as it can
promote DNA-looping between E2 dimers bound at distant sites
in vitro (Antson et al., 2000; Hernandez-Ramon et al., 2008). A very
different TAD dimerization interface was identiﬁed for BPV1 E2.
Sanders et al. (Sanders et al., 2007) reported that the BPV1 E2 TAD
can dimerize, in a redox-dependent manner, in part through the
formation of a disulﬁde bond between cysteine 57 (C57) of two
adjacent monomers. They also identiﬁed other interactions mediat-
ing dimer formation; namely a pair of hydrogen bonds between
glutamine 12 (Q12) and arginine 68 (R68) and an ion pair between
arginine 172 (R172) and aspartic acid 175 (D175) (Sanders et al.,
2007). Biochemical studies provided evidence that this mode of
dimerization occurs between TADs within the same E2 dimer, rather
than between separate dimers. In vitro, the puriﬁed BPV1 E2 TAD
was found to dimerize under non-reducing conditions, a phenom-
enon that could be abolished by substitution to alanine of either C57
or R172 and, to a lesser extent, of D175. The locations of C57, R172Fig. 1. Structure of the BPV1 E2 TAD dimer showing the location of amino
acids mutated in this study. (A) Surface and (B) ribbon diagram of the E2 TAD
dimer (PDB accession code 2jeu). The two TAD monomers are colored in red and
blue, respectively. (C) Location of C57, R172 and D175. C57 is visible only in the
blue monomer and is colored in red. R172 and D175 are visible only in the red
monomer and are colored in blue. Filled arrows point to residues on the visible
face of each monomer while dashed arrows point to the analogous residues
located on the hidden face of the opposite monomer. Images were generated with
PyMol.and D175 within the crystal structure of the BPV1 E2 TAD are shown
in Fig. 1. Despite the clear demonstration that dimerization of the
TAD occurs in vitro under oxidizing conditions, it is unclear if it also
occurs in vivo. Unfortunately, demonstrating the speciﬁc dimeriza-
tion of the TAD in vivo is likely to be technically challenging given
that full-length E2 dimerizes primarily via its C-terminal DBD. In
this study, we have opted to investigate the function of the putative
TAD dimerization interface in vivo by characterizing the effect of the
C57A, R172A and R175A substitutions, either alone or in combina-
tion, on the transactivation and DNA replication activities of BPV1
E2 in transfected cells. Our results suggest that the TAD dimerization
interface is not essential for either function of BPV1 E2 but may play
a role in its DNA replication activity.Results
Expression of BPV1 E2 mutant proteins with amino acid substitutions
in the TAD dimerization interface
As a ﬁrst step towards determining the function of the TAD
dimerization interface in vivo, we constructed plasmids expressing
untagged BPV1 E2 from the CMV promoter, either the wild type
protein or mutant derivatives bearing the C57A, R172A and D175A
substitutions alone or in combination. In the remainder of this paper,
we will refer to these three substitutions as CA, RA and DA,
respectively. These vectors were transfected into C33A human
cervical carcinoma cells and the expression of E2 assessed 24 h later
byWestern blotting using the anti-BPV1 E2 antibody 1E4 (Kurg et al.,
1999). Five different experiments were performed using separate
DNA preparations for transfection. All ﬁve Western blots yielded
similar results and were analyzed by densitometry to determine the
average expression level of each mutant protein relative to that of
wild type E2, which was set at 100% (Table 1). One of the blots is
shown in Fig. 2A. All seven E2 mutant proteins were expressed at the
anticipated molecular weight albeit some at lower levels than wild
type E2 (Fig. 2A). The CA single and CA/RA/DA triple mutant proteins
were the least expressed, at levels approximately 50–55% that
of wild type E2 (po0.0001). The two double mutant proteins
containing the CA substitution (CA/RA and CA/DA) also consistently
displayed reduced expression, accumulating at levels approximately
80–85% that of wild type E2, although these differences did not reach
statistical signiﬁcance. The RA single mutant protein was the only
one that was consistently expressed at slightly higher levels thanTable 1
Summary of the expression and activities of BPV1 E2 mutant proteins.
BPV1 E2 Expression Transactivation DNA replication
%a p-valueb AUC (%)c p-valued AUC (%)e p-valued
WT 100 100712 100732
CA 52710 o0.0001 5477 o0.0001 5873 o0.0001
RA 126718 0.03 9678 ns 9173 ns
DA 104721 ns 9477 ns 7073 0.005
CA/RA 80717 ns 8478 0.03 3071 o0.0001
CA/DA 86715 ns 7178 o0.0001 4674 o0.0001
RA/DA 102711 ns 6476 o0.0001 6774 0.002
CA/RA/DA 5379 o0.0001 5175 o0.0001 3872 o0.0001
AUC¼Area under the curve.
ns¼Statistically not signiﬁcant.
a From Fig. 2A.
b Variance relative to WT E2 assessed by one-way ANOVA followed by
Dunnett’s post-hoc analysis.
c From Fig. 3A.
d Variance relative to WT E2 assessed by two-way ANOVA followed by
Dunnett’s post-hoc analysis.
e From Fig. 6A.
Fig. 2. Expression and intracellular localization of BPV1 E2 mutant proteins.
(A) Representative Western blot analysis of C33A cells transiently expressing the
indicated wild type (WT) or mutant E2. Untagged E2 proteins were detected with
the 1E4 antibody. Half (1/2) and one quarter (1/4) of the amount of WT E2-
containing extract were used as standards. b-tubulin was used as a loading
control. The bar graph shows the expression levels of WT and mutant E2 proteins
quantiﬁed from ﬁve independent Western blots, including the one presented in
panel A. Standard deviations are indicated. (B) The intracellular localization of
untagged wild type or CA/RA/DA triple mutant E2 was determined in transiently
expressing C33A cells by immunoﬂuorescence confocal microscopy using the 1E4
antibody. Nuclei were stained with DAPI. The percentages of transfected cells
showing accumulation of E2 either exclusively in the nucleus (N), or in both the
nucleus and cytoplasm (NC), were derived from the analysis of 300 cells and are
indicated on the left.
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accumulated at wild type levels. Collectively, these results indicate
that substitutions in the TAD dimerization interface do not drama-
tically alter the expression of BPV1 E2, the levels of the protein being
reduced at the most by half in the case of the CA and CA/RA/DA
substitutions.
The integrity of the TAD dimerization interface is not required for the
nuclear localization of BPV1 E2
Wild type BPV1 E2 accumulates primarily in the nucleus of
transfected cells. To test if the TAD dimerization interface is required
for nuclear accumulation of E2, we compared the intracellularlocalization of the CA/RA/DA triple mutant protein to that of wild
type E2 by immunoﬂuorescence in transfected C33A cells, using the
1E4 antibody. As expected, the signal intensity of the CA/RA/DA
protein was weaker than that of wild type E2, conﬁrming its lower
expression. More importantly, the intracellular distribution of the
mutant protein was similar to that of wild type E2; the protein being
exclusively nuclear in approximately two-third of the cells and
present in both the nucleus and cytoplasm in the remaining third
(Fig. 2B). Both the wild type and mutant E2 accumulated within
discrete foci when in the nucleus, as previously reported (Baxter et al.,
2005; Oliveira et al., 2006; Penrose and McBride, 2000). The more
punctate appearance of cells expressing the triple mutant E2 protein
simply reﬂects its lower expression; indeed cells in which wild type
E2 was expressed a lower levels also appeared more punctate (data
not shown). From these results, we conclude that residues C57, R172
and D175 are not required for the nuclear accumulation of BPV1 E2
and, by extension, that the integrity of the TAD dimerization interface
is also not needed for this process.
Transcriptional transactivation activities of the BPV1 E2 mutant
proteins
Next, we tested the ability of the different E2 proteins to
transactivate a ﬁreﬂy luciferase (Fluc) gene under the control of
four E2-binding sites. C33A cells were transfected with increasing
amounts of E2 expression vector and constant amounts of the
Fluc reporter gene and of an internal control vector for normal-
ization (pRL, expressing Renilla luciferase from the CMV promoter
(Fradet-Turcotte et al., 2010)). The levels of luciferase activities
were measured 24 h post transfection and the normalized values
used to calculate the fold-transactivation of the reporter gene
presented in Fig. 3A. Under our assay conditions, wild type BPV1
E2 could transactivate the reporter gene nearly 10-fold at the
highest concentration of expression vector tested. All of the
mutant proteins showed reduced level of transactivation but
none were completely defective for this activity. As an approx-
imation of the transcriptional activities of the different E2
proteins, we measured the area under the curve (AUC) generated
for each protein. These AUC values, presented in Table 1 relative
to the AUC determined for wild type E2 (set at 100%), allowed for
the different E2 proteins to be compared. The transcriptional
activities of the RA and DA single mutant proteins were not
statistically different from that of wild type E2. The activity of the
CA/RA protein was only slightly lower than wild type (p¼0.03). In
contrast, the remaining four mutant proteins, CA, CA/DA, RA/DA
and CA/RA/DA, were all signiﬁcantly less potent at transactivating
the reporter gene than wild type E2 (po0.001). The CA single and
CA/RA/DA triple mutant proteins were the least active, displaying
50–55% of the activity of wild type E2 (Fig. 3A and Table 1), a
result suggesting that C57 is important, albeit not essential, for
the transcriptional activity of E2. Because these two proteins were
the least expressed (Fig. 2A), we wondered if their reduced
transactivation activity was a consequence of their lower
steady-state levels. To test this hypothesis, we repeated the
transactivation assay with the CA/RA/DA triple mutant protein
but this time using higher amounts of E2-expression vector to
saturate the reporter gene. As can be seen in Fig. 3B, titration of
increasing amounts of wild type E2 resulted in high levels of
transactivation that reached a plateau at approximately 23-fold.
As for the CA/RA/DA triple mutant protein, it could transactivate
the reporter gene essentially to the same level as wild type E2,
indicating that it is in not inherently defective for this activity.
However, the amount of E2 expression vector required to achieve
half-maximal transactivation of the reporter gene (EC50) was
approximately 2.5-fold higher for the triple mutant protein
(EC50¼12 ng) than for wild type E2 (EC50¼5 ng). These results
Fig. 3. Transcriptional activities of wild type and mutant BPV1 E2.
(A) Transcriptional activities of wild type (WT) and mutant E2 proteins obtained
at increasing amounts of E2-expression vector. The dose–response curve obtained
for WT E2 is repeated in each graph for comparison. Transcriptional activities were
determined from C33A cells co-transfected with a ﬁreﬂy luciferase reporter gene
under the control of four E2-binding sites and increasing amounts of E2-expres-
sion vector (from 0.03 to 0.50 ng in two-fold increments). A Renilla luciferase
expression plasmid was used for normalization. The values are reported as ‘‘fold-
transactivation’’ of the reporter gene calculated relative to the level measured in
absence of E2 (), which was set at 1. The transcription-defective BPV1 E2 R37A/
I73A mutant protein was used as a control (Ctl) (Abroi et al., 1996; Breiding et al.,
1996; Brokaw et al., 1996; Ferguson and Botchan, 1996; Grossel et al., 1996). For
each of the indicated E2 protein, the dose–response curve that is presented was
obtained from two independent experiments, each done in duplicates using a
separate plasmid preparation (i.e., each dose–response curve is the average of four
determinations). (B) Same as in panel A but using higher amounts of E2 expression
vector (from 0.016 to 150 ng in 2.5-fold increments). The data was ﬁtted to a
sigmoidal dose–response curve using the following equation: Y¼1þ(Top1)/
(1þ10^((LogEC50X)n)) in which Y is the fold-transactivation value, Top is the
maximal level of transactivation achieved at saturating amount of E2 expression
vector, X is the amount of E2 expression plasmid (in grams) and n is the hill
coefﬁcient. ‘‘Goodness-of-ﬁt’’ values were R2¼0.98 for WT E2 and R2¼0.97 for the
CA/RA/DA triple mutant protein.
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tive for transactivation and suggest that its 2.5-fold lower activity
observed at sub-saturating levels of expression vector (Fig. 3A) is
mostly a reﬂection of it reduced steady state accumulation. From
these results, we conclude that amino acids C57, R172 and D175
are not absolutely required for the intrinsic transactivation
activity of E2. By extension, we surmise that the integrity of the
TAD dimerization interface is also not essential for this activity.
Development of a luciferase-based BPV1 DNA replication assay
To compare the DNA replication activities of the different BPV1 E2
mutant proteins, we ﬁrst established a quantitative, transient BPV1
DNA replication assay based on a luciferase readout, essentially as
we reported previously for HPV31 (Fradet-Turcotte et al., 2010)
(Fig. 4). The assay is based on a plasmid containing both the BPV1
origin of DNA replication and a CMV-Fluc reporter gene (pFLORI-
BPV1, Fig. 4A), whose replication by E1 and E2 in C33A cells results in
increased Fluc expression. A second plasmid expressing Rluc from
the CMV promoter (pRL, lacking an origin, Fig. 4A) is used as an
internal control, allowing the DNA replication results to be quantiﬁed
as Fluc/Rluc ratios. To validate this assay, we conﬁrmed that
replication of the CMV-Fluc plasmid was dependent on the presence
of the BPV1 origin and on expression of E1 and E2 (Fig. 4B). Two
different origin fragments were tested, either a short one (nt 7891-31
in the BPV1 genome sequence, Genbank accession X02346.1) or a
longer one (nt 7476-57) (Piirsoo et al., 1996)), with comparable
results (Fig. 4B). Similarly, two different E1-expression vectors were
compared, either pCG E1Eag 1235 , which contains a mutation of
the major splice site located within the E1 ORF, or a precursor
plasmid lacking this mutation. It was previously shown that muta-
tion of this splice site results in higher levels of DNA replication,
presumably because of increased E1 expression (Ustav and Stenlund,
1991). Our results conﬁrmed this ﬁnding, as shown by the observa-
tion that the splice site mutation increased DNA replication by
approximately 5-fold (Fig. 4B). For the remainder of this study, the
assay will be performed with the E1 expression vector containing the
splice site mutation in combination with the ﬁreﬂy luciferase vector
carrying the long origin. To further validate this novel assay, we
veriﬁed that replication of the ori-plasmid could be inhibited by the
known DNA replication inhibitors hydroxyurea (EC50¼470 mM),
gemcitabine (EC50¼6 nM) and aphidicolin (EC50¼164 nM) (Fig. 5).
From these results, we conclude that the levels of ﬁreﬂy luciferase
measured in our assay increase as a function of ori-plasmid replica-
tion by E1 and E2.
DNA replication activities of the BPV1 E2 mutant proteins
The luciferase assay presented above was then used to measure
the DNA replication activities of the different E2 mutant proteins, at
increasing amounts of expression vector, 72 h following transfection
in C33A cells. These studies revealed that all 7 mutant proteins were
defective but not completely inactive in supporting transient DNA
replication (Fig. 6A). To estimate the DNA replication activity of each
mutant protein relative to that of wild type, we measured the area
under the curve (AUC) generated for each E2 protein (Table 1),
essentially as we did in Fig. 3 to assess their transcriptional activity.
All E2 mutant proteins were found to have a statistically signiﬁcant
lower DNA replication activity that wild type E2, except for the RA
protein. The CA/RA double and CA/RA/DA triple mutant proteins
were the least active, displaying approximately 30–40% the activity
of wild type E2. To determine if the lower activity of the CA/RA/DA
triple mutant E2 was due to its lower expression level or to an
intrinsic DNA replication defect, we repeated the DNA replication
assay using higher and saturating amounts of E2 expression vector.
Under these conditions, the maximal level of replication obtained
Fig. 4. Development of a luciferase-based BPV1 DNA replication assay. (A) Schematic representation and names of the plasmids used in this assay. The location of the
BPV1 origin of replication in pFLORI-BPV1 is indicated by a black box. Two different ori-fragments were used, a short and a long one, whose nucleotide boundaries within
the BPV1 genome are indicated in italics above and below the black box. The nucleotide boundaries of the E1 and E2 coding regions are also indicated. Plasmid pCG E1Eag
1235 used to express E1 was published previously (Ustav and Stenlund, 1991) and contains a fragment of the BPV1 genome, spanning nucleotides 619–4010, in which
the major splice site at nucleotide 1235 was mutated (E1 SM in panel (B)) and the sequences between nucleotides 2776–3881 deleted (del). A version of this plasmid
retaining the major splice site was also used (E1 WT in panel (B)) (B) DNA replication activities measured in C33A cells transfected with increasing amounts of expression
vectors for E1 (either WT or SM) and E2 (each from 0.78 to 50 ng in two-fold increments) together with pFLORI-BPV1 containing the short or long origin, as indicated.
Plasmid pCI-Fluc, lacking the ori (no ori), was used as a negative control. DNA replication activities are expressed as Fluc/Rluc ratios and were measured 72 h post
transfection.
Fig. 5. Sensitivity of the luciferase-based BPV1 DNA replication assay to DNA replication inhibitors. EC50 curves were generated using 12-concentrations of
hydroxyurea, gemcitabine and aphidicoline. Each point is the average of duplicate values with standard deviations indicated. C33A cells were co-transfected with the ori,
E1, E2 and control plasmids and treated for 24 h with each compound starting 4 h post transfection.
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wild type protein (Fig. 6B). These results suggest that the CA/RA/DA
mutant E2 is intrinsically deﬁcient for DNA replication. Collectively,
the results presented above point to the TAD dimerization interface
as being important, albeit not essential, for viral DNA replication. As
in any mutational analysis, however, we cannot rule out that the CA,
RA and DA substitutions also affect DNA replication by another yet-
undeﬁned mechanism distinct from interfering with dimerization of
the TAD.Discussion
The BPV1 E2 TAD dimerization interface was discovered and
extensively characterized in vitro by Sanders et al. (Sanders et al.,
2007). This study is the ﬁrst to investigate the role of this TAD
dimerization interface in vivo. To do so, we took advantage of the
three amino acid substitutions, CA, RA and DA, previously shown
by Sanders et al. to signiﬁcantly reduce dimerization of the TAD
in vitro. Our results, summarized in Table 1, indicate that the CA
Fig. 6. DNA replication activities of wild type and mutant BPV1 E2. (A) The
DNA replication activities of wild type (WT) and mutant E2 proteins obtained at
increasing amounts of E2-expression vector. The dose–response curve obtained
for WT E2 is repeated in each graph for comparison. DNA replication activities
were determined from C33A cells co-transfected with a plasmid that encodes
the BPV1 origin and a ﬁreﬂy luciferase (Fluc) reporter gene (pFLORI-BPV1),
together with an E1-expression plasmid (pCG E1Eag 1235) and increasing
amounts of E2-expression vector (from 0.03 to 0.50 ng in two-fold increments).
A Renilla luciferase (Rluc) expression plasmid was used for normalization.
The DNA-replication values are reported as Fluc/Rluc ratios. The partially
replication-defective BPV1 E2 R47Q/K48Q/K49Q/R58Q/H61N mutant protein (D2
mutant in (Baxter et al., 2005)) was used as a control (Ctl). For each of the
indicated E2 protein, the dose–response curve that is presented was
obtained from two independent experiments, each done in duplicates using a
separate plasmid preparation (i.e., each dose–response curve is the average
of four determinations). (B) Same as in panel A but using higher amounts
of E2 expression vector (from 0.016 to 150 ng in 2.5-fold increments). The
data was ﬁtted to a sigmoidal dose–response curve using the following equation:
Y¼Bottomþ(TopBottom)/(1þ10^((LogEC50X)n)) in which Y is the DNA
replication value, Bottom is the DNA replication value measured in absence
of E2, Top is the maximal level of DNA replication obtained at saturating amounts
of E2 expression plasmid. X is the amount of E2 expression plasmid (in grams),
and n is the Hill coefﬁcient. ‘‘Goodness-of-ﬁt’’ values were R2¼0.98 for
WT E2, R2¼0.96 for the CA/RA/DA triple mutant protein and R2¼0.98 for the
control protein.
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had generally the greatest effect on the expression, transcrip-
tional activity and DNA replication activity of E2. This is in
contrast to the RA and DA substitutions which, alone or together,
were better tolerated; the largest effect being a 30% reduction in
DNA replication activity imposed by the DA single and RA/DA
double substitutions. The CA substitution should abolish the
possibility of disulﬁde bond formation between adjacent TADs
and thus prevent any form of redox-dependent regulation of this
domain in vivo. Our ﬁnding that the CA single mutant E2 retains
50–60% of transactivation and DNA-replication activities suggests
that formation of a disulﬁde bond between the two C57 of
adjacent TADs is not essential for these functions of E2. These
results are also consistent with those of Sanders et al. indicating
that the CA substitution does not signiﬁcantly impair the inter-
action of E2 with E1 in vitro (Sanders et al., 2007). The formation
of the two salt bridges between R172 and D175 of adjacent TADs
also appears to be non-essential for the transactivation and DNA
replication activities of E2, as both the single (RA and DA) and
double (RA/DA) mutant proteins were well expressed and
retained signiﬁcant levels of transactivation and DNA replication
activity. Collectively, these results indicate that neither the C57–
C57 disulﬁde bond nor the two R172–D175 salt bridges between
adjacent E2 monomers are essential for the expression as well as
transcription and DNA replication activities of E2 in vivo. As such,
they suggest that dimerization of the TAD is not crucial for these
activities, a notion that is in agreement with previous studies
indicating that BPV1 E2 heterodimers containing a single TAD are
functional, albeit at reduced levels compared to full-length E2
homodimers (Kurg et al., 2006, 2009, 2010).
Although not strictly essential, the TAD dimerization interface
may contribute to some extent to the functions of E2, as suggested
by the phenotypes of the double (CA/RA and CA/DA) and triple (CA/
RA/DA) mutant proteins in which formation of the C57 disulﬁde
bond and R172–D175 salt bridges are prevented simultaneously.
These E2 mutant proteins should in theory be the most impaired
for TAD dimerization and, accordingly, displayed the most severe
phenotypes in the DNA replication assay. They were also signiﬁ-
cantly compromised for transactivation, with the exception of the
CA/RA double mutant which retained approximately 85% of the
activity of wild type E2. Not surprisingly, the CA/RA/DA triple
mutant E2 was the least active showing a 50–60% reduction in
transactivation and DNA replication activity. Because it was the
most defective, we chose to further characterize this triple mutant
protein, relative to wild type E2, using full dose–response curves.
The transactivation and DNA replication data could be ﬁtted by
non-linear regression to a classical sigmoid dose–response curve,
with excellent goodness-of-ﬁt values, thus validating the robust-
ness of our assays for characterizing and comparing mutant
proteins (Fig. 3B and Fig. 6B). These studies revealed that the 50%
weaker transcriptional activity of the triple mutant E2 could be
rescued by overexpression of the protein. This ﬁnding suggests that
the triple mutant E2 is transcriptionally compromised primarily
because of its reduced expression and not because it is intrinsically
deﬁcient for this activity. In stark contrast, overexpression of the
triple mutant E2 could not rescue its DNA replication defect, the
activity of the protein remaining approximately 45% that of wild
type E2. This key result suggests that the triple mutant E2 is
intrinsically deﬁcient for some aspect of viral DNA replication.
As such, it raises the possibility that the TAD dimerization inter-
face, although not essential for BPV1 DNA replication, may be
required structurally and/or functionally for this process.
Although the single, double or triple amino acid substitutions
that we introduced in the TAD did not completely abolished the
transactivation and DNA replication activities of E2, some could
D. Gagnon et al. / Virology 439 (2013) 132–139138nevertheless have dramatic effects on the BPV1 life cycle. Indeed, it
has been observed previously that many amino acid substitutions
in E2 that only partially reduce its transactivation and/or DNA
replication activity often impose a more severe phenotype in
longer-term assays involving the maintenance and/or segregation
of the viral episome in immortalized proliferating cells (Abroi et al.,
2004; Brokaw et al., 1996). As an example relevant to this study,
Kurg et al. (2006) observed that an E2 heterodimer carrying a
single TAD is only partially defective in a transient transactivation
assay but severely compromised in a BPV plasmid segregation
assay performed over several cell divisions; the phenotype in each
assay likely being caused by the weaker binding of the single TAD
E2 to the cellular protein Brd4, a key mediator of E2’s transcription
and segregation activities. By analogy, it is possible that the CA
single and CA/RA/DA triple mutant proteins characterized in this
study, which display 50% transactivation activity, would also be
defective in a segregation assay. Additional studies will be required
to test this possibility and, more generally, to determine the
capacity of these mutant proteins to interact with factors such as
Brd4 and the viral E1 helicase to promote transcription, replication
and segregation of the BPV1 episome. In summary, the results from
our mutational analysis indicate that the TAD dimerization inter-
face is not strictly required for the transactivation and DNA
replication activities of BPV1 E2 in transient assays, but also
support the notion that the two TADs within an E2 dimer are not
completely independent and must productively dimerize for full
activity, in particular to facilitate replication of the viral episome in
infected cells.Materials and methods
Plasmid constructions and mutagenesis
The plasmid used to express untagged BPV1 E2 was constructed
in two steps. First, a BamHI-XbaI digested PCR fragment encoding
the E2 ORF was inserted between the BamHI and XbaI sites of pRluc-
3xFLAG (Gagnon et al., 2009). The following pairs of primers were
used for ampliﬁcation of E2: 50-CCATTGGATCCGAGACAGCATGC-
GAACGTTTACATGT-30 and 50-CCCTCTAGATCAGAAGTCCAAGCTGGC-
TGTAAAGCC-30. In the second step, most of the pRluc-3xFLAG-E2
plasmid, except for the region encoding the Rluc-3xFlag tag, was
ampliﬁed with the following pair of primers, 50-CCCGAATTCATGGA-
GACAGCATGCGAACGTTTACATG-30 and 50-CCCGAATTCGGTGGCTC-
TAGCGGATCTGAC-30, digested with EcoRI and re-circularized. The
resulting plasmid, pBPV1E2, expresses untagged E2 from the CMV
promoter. Mutations in the BPV E2 ORF were constructed using the
Quick Change Site-Directed Mutagenesis kit (Agilent). All DNA
constructs were veriﬁed by sequencing. Further details about their
construction will be made available upon request.Antibodies and Western blotting
For Western blot analysis, proteins were separated by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis and trans-
ferred onto polyvinylidene ﬂuoride membranes. BPV1 E2 was
detected with the mouse monoclonal antibody 1E4 obtained from
Santa Cruz Biotechnology (catalogue no. sc-57644) and used at a
dilution of 1:500. b-tubulin, used as a loading control, was detected
using a monoclonal antibody from Sigma-Aldrich (catalogue
no.T4026) at a dilution of 1:2000. Proteins were visualized using
a horseradish peroxidase-linked sheep anti-mouse secondary anti-
body purchased from GE Healthcare (catalogue no. NA931, used at
a 1:5000 dilution) and the chemiluminescent PLUS Western blot-
ting detection reagents procedure from GE Healthcare. Blots werequantiﬁed using a ChemiDoc MP Imaging System and the Quantity
One 1-D Analysis Software (Bio-Rad).
Cell culture and transfections
Human cervical carcinoma C33A cells were grown in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 50 I.U. of penicillin/ml, 50 mg of streptomycin/
ml and 2 mM of L-glutamine. Transfections were performed using
the Lipofectamine 2000 reagent according to the manufacturer’s
instructions (Invitrogen).
Confocal ﬂuorescence microscopy
C33A cells were grown on coverslips. For immunoﬂuorescence,
cells were ﬁxed 24 h transfection with 4% formaldehyde, permea-
bilized with 0.2% Triton X-100, and incubated with the 1E4 anti-
body diluted 1:200 in PBS-2% milk for 1.5 h, followed by 1 h of
incubation with a 1:1000 dilution of Alexa Fluor 633-conjugated
secondary antibody. Cells were washed with PBS between each step
and then mounted using VectaShield mounting medium (Vector
Laboratories). Images were acquired using a LSM510 confocal laser
coupled to an Axiovert 100M inverted scanning microscope (Zeiss,
Toronto, Ontario, Canada) and analyzed by using LSM Image
Browser version 3.2.0.70 (Zeiss).
Transient transactivation assay
Transactivation assays were performed in 96-wells plates in
which C33A cells were plated 24 h before transfection at a density
of 25,000 cells. Transfection reactions contained increasing quan-
tities of E2-expression plasmid, as indicated in the text, completed
with the appropriate amount of pCI plasmid (Promega) in order to
maintain constant the total amount of DNA in each well. Transfec-
tions reactions also contained 160 ng of pK4xE2BS reporter plas-
mid expressing ﬁreﬂy luciferase under the control of four E2
binding sites (kind gift from Laimonis A. Laimins, Northwestern
University) and 0.5 ng of the pRL control vector expressing Renilla
luciferase. Dual-luciferase measurements were performed 24 h
post transfection as described above.
Transient BPV1 DNA replication assay
This assay was developed and performed essentially as
described previously for HPV31 (Fradet-Turcotte et al., 2010)
but using E1, E2 and the origin of DNA replication from BPV1.
Brieﬂy, 20104 C33A cells were transfected with four plasmids
encoding, respectively, E1 (pCG E1Eag 1235) (Ustav and
Stenlund, 1991), E2 (pBPV1E2), the origin of DNA replication in
cis of a ﬁreﬂy luciferase reporter gene (pFLORI-BPV1), and Renilla
luciferase (pRL). Under standard conditions, 0.03 to 0.50 ng of E2-
expression vector, in two-fold increments, were used along with
constant amounts of the other plasmids (20 ng of pCG E1Eag
1235 , 2.5 ng of pFLORI-BPV1, and 0.5 ng of pRL). For all condi-
tions, replication of the origin-containing plasmid was quantiﬁed
72 h post transfection by measuring the levels of ﬁreﬂy and
Renilla luciferase activities using the Dual-Glo luciferase assay
system (Promega). EC50 values for hydoxyurea, gemcitabine and
aphidicoline were calculated with the GraphPad Prism 5 software
by ﬁtting the data to the following equation: % DNA replica-
tion¼Lowþ(100Low)/(1þ10^((LogEC50[I])n)), in which
Low represents the lowest percentage of DNA replication reached
at saturating amounts of inhibitor, [I] is the concentration of the
inhibitor (M), and n is the Hill coefﬁcient.
D. Gagnon et al. / Virology 439 (2013) 132–139 139Statistical analysis
ANOVA with Dunnett’s post-hoc analysis, as well as calculation
of AUC values, were performed using GraphPad Prism version 6.00.Acknowledgments
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